BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34944658)

  • 1. Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas.
    Schümann FL; Groß E; Bauer M; Rohde C; Sandmann S; Terziev D; Müller LP; Posern G; Wienke A; Fend F; Hansmann ML; Klapper W; Rosenwald A; Stein H; Dugas M; Müller-Tidow C; Wickenhauser C; Binder M; Weber T
    Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
    Yamagishi M; Hori M; Fujikawa D; Ohsugi T; Honma D; Adachi N; Katano H; Hishima T; Kobayashi S; Nakano K; Nakashima M; Iwanaga M; Utsunomiya A; Tanaka Y; Okada S; Tsukasaki K; Tobinai K; Araki K; Watanabe T; Uchimaru K
    Cell Rep; 2019 Nov; 29(8):2321-2337.e7. PubMed ID: 31747604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
    Honma D; Kanno O; Watanabe J; Kinoshita J; Hirasawa M; Nosaka E; Shiroishi M; Takizawa T; Yasumatsu I; Horiuchi T; Nakao A; Suzuki K; Yamasaki T; Nakajima K; Hayakawa M; Yamazaki T; Yadav AS; Adachi N
    Cancer Sci; 2017 Oct; 108(10):2069-2078. PubMed ID: 28741798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Epigenetic aberrations in adult T-cell leukemia/lymphoma and development of a novel EZH1/2 inhibitor].
    Yamagishi M
    Rinsho Ketsueki; 2018; 59(4):432-438. PubMed ID: 29743404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant differential expression of EZH1 and EZH2 in Polycomb repressive complex 2 among B- and T/NK-cell neoplasms.
    Abdalkader L; Oka T; Takata K; Sato H; Murakami I; Otte AP; Yoshino T
    Pathology; 2016 Aug; 48(5):467-82. PubMed ID: 27311868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma.
    Dou F; Tian Z; Yang X; Li J; Wang R; Gao J
    Drug Discov Ther; 2022 Dec; 16(6):297-299. PubMed ID: 36310058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors.
    Shinohara H; Sawado R; Nakagawa M; Hattori A; Yamagata K; Tauchi K; Ito J; Kuwahara Y; Okuda T; Ogawa C; Kitabayashi I
    Mol Ther Oncolytics; 2022 Dec; 27():14-25. PubMed ID: 36212776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
    Yang X; Li F; Konze KD; Meslamani J; Ma A; Brown PJ; Zhou MM; Arrowsmith CH; Kaniskan HÜ; Vedadi M; Jin J
    J Med Chem; 2016 Aug; 59(16):7617-33. PubMed ID: 27468126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polycomb Repressive Complex 2 Proteins EZH1 and EZH2 Regulate Timing of Postnatal Hepatocyte Maturation and Fibrosis by Repressing Genes With Euchromatic Promoters in Mice.
    Grindheim JM; Nicetto D; Donahue G; Zaret KS
    Gastroenterology; 2019 May; 156(6):1834-1848. PubMed ID: 30689973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner.
    Mochizuki-Kashio M; Aoyama K; Sashida G; Oshima M; Tomioka T; Muto T; Wang C; Iwama A
    Blood; 2015 Sep; 126(10):1172-83. PubMed ID: 26219303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type, is associated with disease progression and prognosis.
    Liu J; Liang L; Huang S; Nong L; Li D; Zhang B; Li T
    Hum Pathol; 2019 Jan; 83():166-176. PubMed ID: 30218753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH1 in germ cells safeguards the function of PRC2 during spermatogenesis.
    Mu W; Starmer J; Shibata Y; Yee D; Magnuson T
    Dev Biol; 2017 Apr; 424(2):198-207. PubMed ID: 28254491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons.
    Henriquez B; Bustos FJ; Aguilar R; Becerra A; Simon F; Montecino M; van Zundert B
    Mol Cell Neurosci; 2013 Nov; 57():130-43. PubMed ID: 23932971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma.
    Zhang H; Lv H; Jia X; Hu G; Kong L; Zhang T; Li L; Pan Y; Zhai Q; Meng B; Wang X; Wang H; Wang X
    Oncol Lett; 2019 Aug; 18(2):1415-1423. PubMed ID: 31423206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
    Konze KD; Ma A; Li F; Barsyte-Lovejoy D; Parton T; Macnevin CJ; Liu F; Gao C; Huang XP; Kuznetsova E; Rougie M; Jiang A; Pattenden SG; Norris JL; James LI; Roth BL; Brown PJ; Frye SV; Arrowsmith CH; Hahn KM; Wang GG; Vedadi M; Jin J
    ACS Chem Biol; 2013; 8(6):1324-34. PubMed ID: 23614352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
    Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO
    Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57
    Li W; Bi C; Han Y; Tian T; Wang X; Bao H; Xu X; Zhang X; Liu L; Zhang W; Gao H; Wang H; Zhang H; Meng B; Wang X; Fu K
    Cancer Biol Med; 2019 Aug; 16(3):530-541. PubMed ID: 31565482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ezh1 Targets Bivalent Genes to Maintain Self-Renewing Stem Cells in Ezh2-Insufficient Myelodysplastic Syndrome.
    Aoyama K; Oshima M; Koide S; Suzuki E; Mochizuki-Kashio M; Kato Y; Tara S; Shinoda D; Hiura N; Nakajima-Takagi Y; Sashida G; Iwama A
    iScience; 2018 Nov; 9():161-174. PubMed ID: 30396150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.
    Kim SH; Yang WI; Min YH; Ko YH; Yoon SO
    Tumour Biol; 2016 Feb; 37(2):2037-47. PubMed ID: 26337274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The methyltransferases enhancer of zeste homolog (EZH) 1 and EZH2 control hepatocyte homeostasis and regeneration.
    Bae WK; Kang K; Yu JH; Yoo KH; Factor VM; Kaji K; Matter M; Thorgeirsson S; Hennighausen L
    FASEB J; 2015 May; 29(5):1653-62. PubMed ID: 25477280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.